Jain Global’s Intellia Therapeutics NTLA Stock Holding History

Jain Global’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-67,130	Closed	-$783K	–	1261
2024 Q4	$783K	Buy	+67,130	New	+$1.05M	0.02%	362

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jain Global's NTLA Position: Q1 2025 in Review

Jain Global sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 67,130 shares — an estimated $783K sold.

Jain Global first reported a position in NTLA in Q4 2024 and held it in 1 quarter. The position peaked at $783K in Q4 2024. 294 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

Jain Global reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
Jain Global sold 67,130 Intellia Therapeutics shares in Q1 2025, an estimated $783K.
Jain Global first reported a position in Intellia Therapeutics in Q4 2024 and held it in 1 quarter.
Jain Global's Intellia Therapeutics position peaked at $783K in Q4 2024.
294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Jain Global's 13F filing for Q1 2025, filed 15 May 2025.